BEIJING, Sept 11 — The Chinese biotech firm, Sinovac Biotech, said on Monday that it had started Phase 2 trial of its SA55 injection, which it hopes will be approved as a Covid-19 treatment, reported German news agency (dpa).
The Phase 1 study, which was completed recently, had confirmed the preliminary safety profile of SA55 in 40 healthy adults, aged between 18 and 65, in China.
The Phase 2 study will evaluate the ability of SA55 to reduce SARS-CoV-2 viral load and alleviate clinical symptoms in nearly 150 patients to be enrolled with mild to moderate Covid-19.
— Bernama-dpa
